WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow Infiltrating Lymphocytes (MILs™)
15 oct. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA and IRVINE, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have...
WindMIL Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
30 sept. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE, Md. and PHILADELPHIA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy,...
WindMIL Therapeutics Appoints Urvashi Patel, PhD, as Vice President of Regulatory and Quality Systems
09 sept. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, Sept. 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has...
WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)
09 juil. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA and ANN ARBOR, Mich., July 09, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first...
WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer
25 juin 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE and PHILADELPHIA, June 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced...
WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO
25 avr. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE, Md., April 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth
17 avr. 2019 07h00 HE
|
WindMIL Therapeutics
BALTIMORE, April 17, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the promotions...
WindMIL Therapeutics Appoints Sanjin Zvonić, PhD, as Vice President of Process Science and Manufacturing
25 mars 2019 08h00 HE
|
WindMIL Therapeutics
BALTIMORE, March 25, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
WindMIL Therapeutics Expands Leadership Team and Opens Office in Philadelphia
20 déc. 2018 07h00 HE
|
WindMIL Therapeutics
BALTIMORE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, has announced the...
WindMIL Therapeutics Announces Preclinical Data Demonstrating Marrow-Infiltrating Lymphocytes’ Potential as CAR-Modified T Cell Therapy Platform
03 déc. 2018 07h00 HE
|
WindMIL Therapeutics
BALTIMORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, yesterday announced...